EDAP TMS S.A. (EDAP)

FR — Healthcare Sector
Peers: PDCO  HSIC  ABC  MCK  CAH  OMI  ZYXI 

Automate Your Wheel Strategy on EDAP

With Tiblio's Option Bot, you can configure your own wheel strategy including EDAP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol EDAP
  • Rev/Share 1.7244
  • Book/Share 1.0984
  • PB 1.4352
  • Debt/Equity 0.3404
  • CurrentRatio 1.848
  • ROIC -0.3596

 

  • MktCap 58943724.8908
  • FreeCF/Share -0.4757
  • PFCF -3.3276
  • PE -3.0819
  • Debt/Assets 0.1617
  • DivYield 0
  • ROE -0.4135

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 3
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade EDAP Piper Sandler Overweight Neutral -- -- May 15, 2025
Downgrade EDAP Jefferies Buy Hold -- $2 April 4, 2025

News

EDAP TMS S.A. (EDAP) Q1 2025 Earnings Call Transcript
EDAP
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral

EDAP TMS S.A. (OTCPK:HAGHY) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants John Fraunces - IR, LifeSci Advisors Ryan Rhodes - CEO Ken Mobeck - CFO Conference Call Participants Michael Sarcone - Jefferies Sean Lee - H.C.

Read More
image for news EDAP TMS S.A. (EDAP) Q1 2025 Earnings Call Transcript
EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025
EDAP
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

Company to host conference call and webcast on Thursday, May 15 th at 8:30am EDT LYON, France, May 1, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer.

Read More
image for news EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025
EDAP Announces Significant Presence of Focal One® at the Upcoming 120th American Urological Association (AUA) Annual Meeting
EDAP
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

Activities to include expert-led demonstrations, semi-live Focal One procedures and hands-on simulations Final results of randomized clinical trial (FARP Study) comparing ultrasound-based focal ablation versus radical prostatectomy as a first-line treatment for prostate cancer Presentation on the first ever remote transatlantic Focal One Robotic HIFU procedure will be given by Ruben Olivares, MD, Urologic Surgeon at the Cleveland Clinic, at the AUA session of the Engineering & Urology Society Notable increase in the number of scientific presentations on focal therapy and ablation in the management of prostate cancer Focal One Robotic HIFU Masterclass will be held at the Keck School …

Read More
image for news EDAP Announces Significant Presence of Focal One® at the Upcoming 120th American Urological Association (AUA) Annual Meeting
EDAP TMS S.A. (EDAP) Q4 2024 Earnings Call Transcript
EDAP
Published: March 27, 2025 by: Seeking Alpha
Sentiment: Neutral

EDAP TMS S.A. (NASDAQ:EDAP ) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants John Fraunces - IR, LifeSci Advisors Ryan Rhodes - CEO Ken Mobeck - CFO Conference Call Participants Michael Sarcone - Jefferies Swayampakula Ramakanth - H.C.

Read More
image for news EDAP TMS S.A. (EDAP) Q4 2024 Earnings Call Transcript

About EDAP TMS S.A. (EDAP)

  • IPO Date 1997-08-01
  • Website https://www.edap-tms.com
  • Industry Medical - Devices
  • CEO Mr. Ryan Rhodes
  • Employees 310

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.